Jyong Biotech Ltd. MENS
- Market cap
- $162.6M
- P/E
- —
Follow MENS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 2.60 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 67.00 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 29 | 27 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | (4) | (3) | (5) |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (4) | (3) | (5) |
Net Income
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (0.06) | (0.04) | (0.06) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (0.04) | (0.05) | (0.04) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (0.04) | (0.05) | (0.04) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (0.48) | (0.51) | (0.34) |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 72 | 72 | 73 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | (3) | (4) | (3) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | (3) | (4) | (3) |
FCF
|
|||
| — | — | — | — | — | — | — | (12) | (12) | (19) |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 16 | 18 | 18 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 15 | 18 | 17 |
Net Debt
|
|||
| — | — | — | — | — | — | — | (34) | (37) | (25) |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (41.32%) | (34.42%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 8.55% | 15.21% |
ROE
|
|||
Jyong Biotech Ltd. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ABOS Acumen Pharmaceuticals, Inc. | $161.6M | 0.0× | Compare |
| MOLN Molecular Partners AG Sponsored ADR | $160.5M | 0.0× | Compare |
| ADCT ADC Therapeutics SA | $164.7M | 0.0× | Compare |
| NERV Minerva Neurosciences, Inc | $164.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | $159.5M | 0.0× | Compare |
| TNXP Tonix Pharmaceuticals Holding Corp. | $166.4M | 0.0× | Compare |
| HUMA Humacyte, Inc. | $166.7M | 0.0× | Compare |
| VYGR Voyager Therapeutics, Inc. | $172.5M | 0.0× | Compare |
Jyong Biotech Ltd. (MENS) key facts
- Jyong Biotech Ltd. (MENS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Jyong Biotech Ltd. reported a net loss of $4.7 million, or a loss of $0.06 per share, for fiscal 2025.
- As of September 25, 2026, MENS traded at $2.03, a market capitalization of $162.6 million.
- Return on equity was 15.2% and debt-to-equity -0.74.
Jyong Biotech Ltd. (MENS) Latest News
27 Jul
Jyong Biotech Ltd. highlights the multi-billion dollar global BPH market opportunity and reaffirms its strategic focus on global licensing partnerships. Reaffirmation of licensing strategy in large BPH market supports moderate growth potential without immediate financial shifts.
23 Jul
Jyong Biotech highlights multi-billion dollar global BPH market opportunity and reaffirms strategic focus on global licensing partnerships. Emphasizing large BPH market potential alongside licensing strategy signals major moves likely to alter trajectory and investor sentiment.
31 May
Jyong Biotech CEO detailed FDA regulatory pathway and global expansion plans during PharmaBoardroom live interview. CEO outline of FDA pathway and global strategy signals major regulatory progress and expansion potential for Jyong Biotech.
29 May
Jyong Biotech CEO outlined FDA regulatory pathway and global expansion strategy during PharmaBoardroom live interview. CEO outlining of FDA pathway signals moderate regulatory progress potential without confirmed approvals or launches.
28 Apr
Jyong Biotech Ltd. (MENS) updates market access strategy for innovative botanical drugs, establishing multiple competitive advantages for its new drug portfolio. Strategic market access updates for innovative botanical drugs create multiple competitive advantages, significantly enhancing future performance and investor sentiment.
Jyong Biotech Ltd. (MENS) updates market access strategy for innovative botanical drugs, establishing multiple competitive advantages for its new drug portfolio. Strategic market access updates for botanical drugs establish competitive advantages that could significantly enhance future performance and investor sentiment.
27 Mar
Jyong Biotech Ltd. (MENS) details potential clinical benefits and advantages of its plant-derived innovative drug MCS®-2, emphasizing superior efficacy, safety, and market edge over competitors. Update on MCS®-2's clinical advantages targets key product innovation and competitive positioning with moderate influence on investor sentiment.
12 Feb
Jyong Biotech Ltd. (MENS) has reported significant progress in clinical validation and commercialization efforts, highlighting Phase II data that showcases the dual therapeutic potential of its product MCS-8 in oncology and metabolic health. The company is also strategically entering the Asian market, which could enhance its growth prospects. The dual therapeutic potential of MCS-8 and market entry into Asia are likely to significantly impact future performance and investor sentiment.
Jyong Biotech Ltd. (MENS) has reported significant advancements in clinical validation and commercialization efforts, focusing on Phase II data that highlights the dual therapeutic potential of its product MCS-8 in oncology and metabolic health. The company is also strategically entering the Asian market, which could enhance its growth prospects. The strategic market entry into Asia and promising Phase II data could significantly alter the company's trajectory and investor sentiment.
10 Feb
CEO Fu-Feng Kuo, the largest shareholder of Jyong Biotech Ltd. (NASDAQ:MENS), has seen the value of his holdings decrease by 23% following a recent drop in the company's stock price. This decline raises concerns about the company's market performance and investor sentiment. The significant drop in stock value may moderately influence investor sentiment and financial performance.
30 Jan
Jyong Biotech Ltd.'s subsidiary has announced promising Phase II clinical data for MCS-8 (PCP), showing positive effects on cholesterol and LDH indicators, which may indicate potential in prostate cancer prevention and metabolic value. The Phase II clinical data suggests significant advancements in prostate cancer prevention, potentially altering the company's trajectory and investor sentiment.
4 Dec
Jyong Biotech Ltd. has signed a Memorandum of Understanding (MOU) with a pharmaceutical distributor in Vietnam to facilitate the market entry of its MCS-2 product. This partnership aims to enhance Jyong's regional presence and expand its distribution network in Southeast Asia, aligning with the company's growth strategy. The MOU represents a significant strategic move that could enhance market access and investor sentiment.
24 Nov
Jyong Biotech Ltd. has signed a non-binding letter of intent with a leading South Korean pharmaceutical company to explore the in-licensing of plant-derived MCS drugs. This collaboration aims to evaluate the potential of these drugs in addressing various medical needs, signaling a strategic move to enhance Jyong's product portfolio and market presence. The collaboration with a prominent pharmaceutical company could significantly enhance Jyong's product offerings and market positioning.
21 Nov
Jyong Biotech Ltd. has successfully completed the primary endpoint analysis for its Phase II trial of MCS-8, a significant milestone in the development of this therapeutic candidate. The results are expected to provide crucial insights into the efficacy and safety of MCS-8, potentially paving the way for further clinical advancements and regulatory submissions. Completion of the primary endpoint analysis for a Phase II trial is a significant step that could influence future product development and market positioning.
Jyong Biotech Ltd. (MENS) has experienced notable share price volatility recently, prompting an exploration of its valuation. Analysts are assessing the factors contributing to this fluctuation, including market sentiment and potential impacts on the company's future performance. The analysis aims to provide insights into how these developments may influence investor confidence and the overall trajectory of Jyong Biotech in the competitive biotech landscape. Recent share price volatility indicates a moderately noticeable influence on investor sentiment and potential financial performance.
20 Nov
Jyong Biotech Ltd. (MENS) has announced the successful completion of the primary endpoint statistical analysis for its Phase II clinical trial of MCS-8, yielding positive outcomes. This development marks a significant milestone in the company's research and development efforts, potentially advancing MCS-8 towards further clinical evaluation and market introduction. Positive outcomes from the Phase II clinical trial could significantly influence the company's future product offerings and market position.
29 Sep
Jyong Biotech Ltd. (MENS) has been awarded the Innovation Gold Award in the Pharmaceutical Category at the 2025 Taipei Biotech Awards, recognizing its advancements and contributions to the biotech industry. Winning a prestigious award can significantly enhance the company's reputation and market positioning.
18 Sep
Jyong Biotech Ltd. Chairwoman and CEO is scheduled to speak at the 2025 Global Business Forum in Taipei, highlighting the company's commitment to global engagement and leadership in the biotech sector. Participation in a global business forum may enhance the company's visibility and networking opportunities, potentially influencing its market positioning.
16 Sep
Jyong Biotech Ltd. has successfully completed patient enrollment for over 700 subjects in its Phase II clinical trial of MCS-8, aimed at prostate cancer prevention. This milestone marks a significant step in the development of the treatment, which is designed to reduce the risk of prostate cancer in at-risk populations. Completion of patient enrollment in a Phase II trial is a significant milestone that could enhance the company's product pipeline and investor sentiment.
14 Sep
Jyong Biotech Ltd. (MENS) has experienced notable price movements recently, prompting an evaluation of its current valuation. Analysts are assessing the implications of these changes on the company's financial health and market position, considering factors such as investor sentiment and competitive landscape. The analysis aims to provide insights into how these price shifts may influence future performance and strategic decisions. Recent price movements indicate a moderately noticeable influence on the company's market positioning and investor sentiment.
22 Aug
Jyong Biotech Ltd. participated in the 22nd Urological Association of Asia Congress, showcasing clinical data from its Phase III studies of BOTRESO and Phase II study of MCS-8 (PCP). The presentation of clinical data at a significant congress could lead to increased investor interest and potential market opportunities.
22 Jul
Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based biotechnology company, completed its Nasdaq IPO and participated in the BIO 2025 International Convention in Boston. The company showcased its flagship product, MCS®-2, targeting benign prostatic hyperplasia (BPH) amidst a growing market projected to reach $9.8 billion by 2026. Chairwoman Fu-Feng Kuo emphasized the company's commitment to plant-based drug innovation and global market expansion, particularly in the U.S., EU, and Asia. The Nasdaq listing and participation in BIO 2025 signify major strategic moves that could significantly alter Jyong Biotech's market positioning and investor sentiment.